BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11926387)

  • 1. Visualisation and assessment of the protein synthesis rate of lung cancer using carbon-11 tyrosine and positron emission tomography.
    Pieterman R; Willemsen A; Appel M; Pruim J; Koëter G; Vaalburg W; Groen H
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):243-7. PubMed ID: 11926387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-1-11C-tyrosine PET in patients with laryngeal carcinomas: comparison of standardized uptake value and protein synthesis rate.
    de Boer JR; Pruim J; van der Laan BF; Que TH; Willemsen AT; Albers FW; Vaalburg W
    J Nucl Med; 2003 Mar; 44(3):341-6. PubMed ID: 12620998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas.
    de Boer JR; van der Laan BF; Pruim J; Que TH; Burlage F; Krikke A; Willemsen AT; Tiebosch AT; Albers FW; Vaalburg W
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1182-7. PubMed ID: 12192563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy.
    Ceriani L; Giovanella L; Bandera M; Beghe B; Ortelli M; Roncari G
    Nucl Med Commun; 1997 Nov; 18(11):1087-97. PubMed ID: 9423210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
    van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
    J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas.
    Plaat B; Kole A; Mastik M; Hoekstra H; Molenaar W; Vaalburg W
    Eur J Nucl Med; 1999 Apr; 26(4):328-32. PubMed ID: 10199937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates.
    Kole AC; Pruim J; Nieweg OE; van Ginkel RJ; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
    J Nucl Med; 1997 Feb; 38(2):191-5. PubMed ID: 9025733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of protein synthesis in the human brain using L-[1-11C]-leucine PET: incorporation of factors for large neutral amino acids in plasma and for amino acids recycled from tissue.
    Sundaram SK; Muzik O; Chugani DC; Mu F; Mangner TJ; Chugani HT
    J Nucl Med; 2006 Nov; 47(11):1787-95. PubMed ID: 17079811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of survival and therapy outcome with 11C-tyrosine PET in patients with laryngeal carcinoma.
    de Boer JR; Pruim J; Albers FW; Burlage F; Vaalburg W; van der Laan BF
    J Nucl Med; 2004 Dec; 45(12):2052-7. PubMed ID: 15585481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience.
    de Jong IJ; Pruim J; Elsinga PH; Jongen MM; Mensink HJ; Vaalburg W
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1283-8. PubMed ID: 12271408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography.
    Miles KA; Griffiths MR; Keith CJ
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):22-8. PubMed ID: 16180030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
    Choi NC; Fischman AJ; Niemierko A; Ryu JS; Lynch T; Wain J; Wright C; Fidias P; Mathisen D
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1024-35. PubMed ID: 12419428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.